

Document Type		Form
Index Number		Registry 133
Version Number		1.0
Title		IST FU annual
Author	I	Annelot van Amerongen
Authorised By	I	Annelot van Amerongen
Authorised On	I	22-Aug-2023
Release Date:		22-Aug-2023



Treatment Type	🗌 IST
----------------	-------

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

IMMUNOSUPPRESSIVE TREATMENT (IST) --- Annual/Unscheduled Follow-Up ---

SURVIVAL S	TATUS
------------	-------

Date of follow-up: _	//	_(YYYY/MM/DD)
(if died: date of death,	if lost to follow	ı up: date last seen)

Sur	vival	status:

☐ Alive

Dead

Lost to follow-up

Date of the last IST for this p	atient: / _	_/	(YYYY/MM/DD)
---------------------------------	-------------	----	--------------

BEST RESPONSE

Best res	ponse since	the last follow-u	p (even	if the resp	ponse got	worse again	afterwards):

 Stable disease / No change / No response Complete remission (CR) Partial remission (PR) Haematological improvement (HI); <i>NIH partial response</i> Relapse / Progression Not evaluated Unknown Date best response observed:I(YYY/MM/DD) 						
Transfusions since last follow-up:						
RBC: < 20 units F 20 - 50 units > 50 units None Unknown	RBC irradiated: Yes Unknown					
Platelets: C < 20 units F 20 - 50 units > 50 units None Unknown	Platelets irradiated: No Yes Unknown					
	FIRST RELAPSE AFTER IST					
Complete this section only for <u>the first</u> relapse after this IST. First relapse/progression of Aplastic Anaemia (detected by any method):						
 No Index: Registry 133 Title: IST FU annual Version: 1.0 Effective Date: 2023-08-22 THIS IS AN UNCONTOLLED COPY Yes: Date of relapse:// (YYYY/MM/DD) 						



EBMT Centre Identification Code (CIC):	Treatment Type	🔲 IST	
Hospital Unique Patient Number (UPN):			
Patient Number in EBMT database:	Treatment Date	/_/	(YYYY/MM/DD)

LAST DISEASE STATUS

Disease status this follow-up:

(disease status on the date the patient was last assessed)

- ☐ Stable disease / No change / No response
- Complete remission (CR)
- Partial remission (PR)
- Haematological improvement (HI); NIH Partial Response
- Relapse / Progression
- □ Not evaluated
- Unknown

COMPLICATIONS SINCE LAST FOLLOW-UP

Adverse events/non-infectious complications grade 2-5 observed (based on CTCAE grades):

🗌 No

Yes (provide details in the table below)

Adverse event	Observed?	Maximum CTCAE grade observed					Onset date (YYYY/MM/DD)
Idiopathic pneumonia syndrome	☐ No ☐ Yes	2	3	4	🔲 5 (fatal)	Unknown	//
Veno-occlusive disease (VOD)	☐ No ☐ Yes	2	3	4	🔲 5 (fatal)	Unknown	//
Cataract	☐ No ☐ Yes	2	3	4	🔲 5 (fatal)	Unknown	//
Haemorrhagic cystitis, non-infectious	☐ No ☐ Yes	□ 2	3	4	🔲 5 (fatal)	Unknown	//
ARDS, non-infectious	☐ No ☐ Yes	□ 2	3	4	🔲 5 (fatal)	Unknown	//
Multiorgan failure, non-infectious	☐ No ☐ Yes	□ 2	3	4	🔲 5 (fatal)	Unknown	//
Renal failure (chronic kidney disease, acute kidney injury)	☐ No ☐ Yes	2	3	4	🔲 5 (fatal)	Unknown	//
Haemolytic anaemia due to blood group	☐ No ☐ Yes	□ 2	3	4	🔲 5 (fatal)	Unknown	//
Aseptic bone necrosis	□ No □ Yes	2	3	4	🗌 5 (fatal)	Unknown	//
Liver disorder	☐ No ☐ Yes	2	3	4	🔲 5 (fatal)	Unknown	//
Cardiovascular event	☐ No ☐ Yes	2	3	4	🔲 5 (fatal)	Unknown	//
Stroke	□ No □ Yes	□ 2	3	4	🔲 5 (fatal)	Unknown	//
Central nervous system (CNS) toxicity	☐ No ☐ Yes	□ 2	3	4	🔲 5 (fatal)	Unknown	//
Endocrine event	□ No □ Yes	□ 2	3	4	5 (fatal)	Unknown	//
Other; specify: Index: Registry 133 Title: IS	ST FU annual Vers	2 on: 1.0	☐ 3 Effective	4 Date: 20		Unknown	



Treatment Type

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

SECONDARY MALIGNANCIES AND AUTOIMMUNE DISORDERS

	Did a secondary malignancy or autoimmune disorder occur?									
C	Yes: was this disease an indication for a subsequent HCT/CT/IST?									
		☐ No (complete the non-indication	diagnosis form)						
		☐ Yes (complete the relevant indica	ation diagnosis	form)						
	BONE MARROW INVESTIGATION									
	Bone marrow investigation:									
	Yes:	Date of bone marrow investigation: _	//	_(YYYY/MM/I	DD)					
	Type of bone marrow investigation:									
		Type of dysplasia:								
		Erythroid dysplasia Granulocyte dysplasia Megakaryocyte dysplasia	☐ No ☐ No ☐ No	☐ Yes ☐ Yes ☐ Yes	 Not evaluated Not evaluated Not evaluated 	Unknown Unknown Unknown Unknown				
	Bone	e marrow assessments:								
	Cellul	arity in the bone marrow aspirate	 Acellul Hypoce Normo Hyperce 	ellular cellular	 Focal cellularity Not evaluated Unknown 	/				
	Cellul	arity in the bone marrow trephine	 Acellular Hypocellular Normocellular Hypercellular 		 Focal cellularity Not evaluated Unknown 	/				
	Fibros	sis on bone marrow biopsy	 No Mild Moderate Severe 		Not evaluableNot evaluatedUnknown					
	CD34	+ cell count	%		☐ Not evaluated	🔲 Unknown				
	Blast	count		%	☐ Not evaluated	Unknown				

Index: Registry 133 | Title: IST FU annual | Version: 1.0 | Effective Date: 2023-08-22 | THIS IS AN UNCONTOLLED COPY



Treatment Type	🗌 IST
----------------	-------

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

CHROMOSOME ANALYSIS

Chromosome analysis done at follow-up (all methods including FISH):

Not done or failed
 Yes, abnormal results
 Yes, normal results
 Unknown

Date of chromosome analysis (if applicable): _ _ / _ / _ (YYYY/MM/DD)

Indicate below whether the abnormalities were absent, present or not evaluated.

Trisomy 8	Absent Present Not evaluated
abn 3	Absent Present Not evaluated
Monosomy 7	Absent Present Not evaluated
del(13q)	Absent Present Not evaluated
Other; specify:	Absent Present

MOLECULAR MARKER ANALYSIS

Molecular marker analysis done at follow-up:

No
Yes

Unknown

Date of molecular marker analysis (if applicable): _ _ / _ / _ (YYYY/MM/DD)

Indicate below whether the markers were absent, present or not evaluated.

ASXL1	Absent	Present	Not evaluated
BCOR	Absent	Present	☐ Not evaluated
BCORL1	Absent	Present	Not evaluated
CBL	Absent	Present	Not evaluated
CSMD1	Absent	Present	Not evaluated
DNMT3A	Absent	Present	Not evaluated
ETV6	Absent	Present	Not evaluated
EZH2	Absent	Present	Not evaluated
FLT3	Absent	Present	Not evaluated
GNAS	Absent	Present	Not evaluated
IDH1	Absent	Present	Not evaluated
IDH2	Absent	Present	Not evaluated
JAK2	Absent	Present	Not evaluated
KRAS	Absent	Present	Not evaluated
MPL	Absent	Present	Not evaluated
NPM1	Absent	Present	☐ Not evaluated
NRAS	Absent	Present	☐ Not evaluated
PHF6 Index: Registry 133	Title: IST FUanAbទុលtersion: 1	.0 Effectivescate: 202	3-08-22 TNPS BY AND BY



Treatment Type	🗌 IST
----------------	-------

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

MOLECULAR MARKER ANALYSIS continued

PIGA	Absent	Present	☐ Not evaluated
PPM1D	Absent	Present	☐ Not evaluated
PTPN11	Absent	Present	☐ Not evaluated
RAD21	Absent	Present	☐ Not evaluated
RUNX1	Absent	Present	☐ Not evaluated
SETBP1	Absent	Present	☐ Not evaluated
SF3B1	Absent	Present	☐ Not evaluated
SRSF2	Absent	Present	☐ Not evaluated
STAG2	Absent	Present	☐ Not evaluated
TET2	Absent	Present	☐ Not evaluated
TP53	Absent	Present	☐ Not evaluated
U2AF1	Absent	Present	☐ Not evaluated
ZRSR2	Absent	Present	Not evaluated

PNH TESTS SINCE LAST FOLLOW-UP

PNH test done:	
□ No	
Yes: Date of PNH test://(YYYY/MM/DD)	Unknown
PNH diagnostics by flow cytometry:	
Clone absent	
Clone present: Size of PNH clone in %:	
Flow cytometry assessment done on:	
Granulocytes	
RBC	
Both	

Index: Registry 133 | Title: IST FU annual | Version: 1.0 | Effective Date: 2023-08-22 | THIS IS AN UNCONTOLLED COPY

(EBM	Т

PNH TESTS SINCE LAST FOLLOW-UP continued

Clinical manifestation of PNH:

🗌 No

Yes: Date of clinical manifestation:	//	(YYYY/MM/DD)	🔲 Unknown
--------------------------------------	----	--------------	-----------

Anti-complement treatment given?

🗌 No

 \square Yes, complete the table:

Drug	Start date (YYYY/MM/DD)	Stop date (YYYY/MM/DD)
🔲 Eculizumab	/_// Unknown	/_// Ongoing Unknown
🔲 Ravulizumab	// Unknown	// Ongoing
Pegcetacoplan	// Unknown	/_// Ongoing
Other; specify*:	// Unknown	// Ongoing

*Please consult the LIST OF CHEMOTHERAPY DRUGS/AGENTS AND REGIMENS on the EBMT website for drugs/regimens names

If there were more drugs given during one line of treatment add more copies of this page.

CAUSE OF DEATH

Main cause of death:

(check only one main cause)

Select treatment related cause: Graft versus Host Disease Non-infectious complication
 Infectious complication: (select all that apply) Bacterial infection Viral infection
 Fungal infection Parasitic infection Infection with unknown pathogen
ective Date: 2023-08-22 THIS IS AN UNCONTOLLED COPY